e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A dose-response study of nilotinib and imatinib in experimental pulmonary hypertension
M. C. Chaumais, F. Perros, M. Molimard, S. Bouchet, P. Dorfmuller, C. Guignabert, S. Cohen-Kaminsky, M. Humbert, D. Montani (Le Plessis Robinson, France)
Source:
Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Session:
Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Session type:
Thematic Poster Session
Number:
3900
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. C. Chaumais, F. Perros, M. Molimard, S. Bouchet, P. Dorfmuller, C. Guignabert, S. Cohen-Kaminsky, M. Humbert, D. Montani (Le Plessis Robinson, France). A dose-response study of nilotinib and imatinib in experimental pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 3900
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
New therapeutic approach for the treatment of monocrotaline-induced pulmonary hypertension with imatinib
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES)
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020
Year: 2020
A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007
Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Source: Eur Respir J 2014; 43: 1691-1697
Year: 2014
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
Source: Eur Respir J 2010; 36: 808-818
Year: 2010
A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept